Original Article

Ouabain-induced apoptosis and inhibition of viability of tubulointerstitial cells by regulating NKA/pSrc/pERK/pAkt/pS6k/caspase 3 may contribute to lupus nephritis development

Changxuan Liu1*, Meiyu Lou1*, Yu Ding2, Yin Wang1, Yunfang Huang1, Danni Shao1, Wenli Chen1

1Division of Nephrology, 2Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China. *Equal contributors.

Received January 10, 2018; Accepted March 14, 2018; Epub May 1, 2018; Published May 15, 2018

Abstract: This study aimed to investigate the underlying molecular mechanism of ouabain-induced apoptosis and inhibited viability of tubulointerstitial cells in lupus nephritis (LN). Serum ouabain expression in 21 LN patients and 20 healthy controls (HCs) was detected by ELISA. Na-K-ATPase α1 (NKA) expression in kidney tissue from 21 LN patients and 6 controls who underwent nephrectomy was determined by immunohistochemistry assay. HK-2 cells were treated by ouabain with concentration 0 nM (control), 0.1 nM, 1 nM, 10 nM, 100 nM and 1000 nM for 72 h; MTT assay was performed at 24 h, 48 h and 72 h to detect cell viability, AV/PI assay was conducted at 24 h to detect the cell apoptosis. NKA expression was detected by immunofluorescence assay and western blot (WB) while pSrc, pERK, pAkt, pS6K and caspase 3 expression was detected by WB after 100 nM ouabain treatment. Serum ouabain was elevated in LN patients compared to HCs, while kidney NKA was reduced in LN patients compared with controls. HK-2 cell viability by MTT assay was decreased while cell apoptosis by AV/PI was increased at each time point after ouabain 0.1 nM, 1 nM, 10 nM, 100 nM and 1000 nM treatment compared to control group. Both immunofluorescence and WB disclosed that NKA expression was decreased at 12 h and 24 h compared to 0 h after 100 nM ouabain treatment. Moreover, pSrc, pERK, pAkt, pS6K and caspase 3 expressions were elevated after 100 nM ouabain treatment. In conclusion, ouabain may contribute to LN etiology by inhibiting human proximal tubular cell viability and promoting cells apoptosis through regulating NKA, pSrc, pERK, pAkt, pS6K and caspase 3.

Keywords: Lupus nephritis (LN), ouabain, Na-K-ATPase α1 (NKA), cell viability, apoptosis

Introduction

Lupus nephritis (LN), as a prototypical human autoimmune disease, is a common and severe manifestation of systemic lupus erythematosus (SLE), which is the leading cause of morbidity and mortality in SLE patients [1-3]. The development and progression of nephritis in patients with SLE results from multiple pathogenic pathways including aberrant apoptosis, autoantibody production, immune complex deposition, and complement activation. Among these causes, aberrant apoptosis which leads to glomerular and/or tubulointerstitial injury plays a critical role in LN etiology [1, 4].

Ouabain, as a cardiotonic steroid endogenously produced in mammals and circulating in plasma, has been observed to regulate a myriad of cell functions by binding/regulating Na-K-ATPase α1 (NKA), including cell proliferation, hypertrophy, apoptosis, mobility, and metabolism [5, 6]. A recent report discloses that ouabain promotes cell apoptosis and autophagy in Burkitt’s lymphoma Raji cells [7]. Another study reveals that ouabain elicits human glioblastoma cell apoptosis by generating reactive oxygen species in an ERK-p66SHC-dependent manner [8]. In kidney diseases, ouabain was discovered to contribute to renal damage in a rat model of renal ischemia-reperfusion injury and it could serve as convincing biomarker for acute kidney injury (AKI) in post cardiac surgery patients [9, 10]. However, the role of ouabain in LN pathogenesis is seldom reported, and considering the role of ouabain in regulating
apoptosis and causing renal injury, we hypothesized that ouabain may be involved in the etiology of LN by regulating tubulointerstitial apoptosis through modulating NKA or its related pathways. Thus this study aimed to investigate the underlying molecular mechanism of ouabain induced apoptosis and inhibited viability of tubulointerstitial cells in LN.

Patients and methods

Participants

A total of 21 LN patients underwent biopsy in The Central Hospital of Wuhan from Dec 2015 to Jun 2016 were consecutively enrolled in this case-control study. SLE was diagnosed according to the 1982 American College of Rheumatology classification criteria, and nephritis was confirmed by pathologic examination of biopsies. In addition, 6 controls without LN who had nephrectomy were consecutively recruited during the same period to compare the Na\(^{+}\)-K\(^{+}\)-ATPase \(\alpha_1\) (NKA) expression in kidney tissue between LN patients and controls. Another 20 healthy controls (HCs) were consecutively included from the same time interval to compare the ouabain concentration in serum between LN patients and HCs.

This study was approved by the Medical Ethics Committee of The Central Hospital of Wuhan and conducted according to the Declaration of Helsinki. All participants or their statutory guardians provided informed consent.

Samples

Kidney tissue samples from 21 LN patients and 6 controls were obtained by biopsy or during the nephrectomy operation, fixed, and embedded in paraffin. Serum samples were acquired from 21 LN patients and 20 HCs when included in this present study. All samples were collected before any therapies such as high-dose corticosteroid, immunoglobulin and others.

Enzyme linked immunosorbent assay (ELISA)

Concentrations of ouabain in serum from LN patients and HCs were detected by ELISA using commercial Human Ouabain ELISA Kit (Beijing Dongge Bio-tech Company, China) according to manufacturer’s instructions.

Immunohistochemistry (IHC) assay

The paraffin-embedded kidney tissue sections (3 mm thick) from LN patients and controls were deparaffinized, treated with 3\% \(\text{H}_2\text{O}_2\) for 15 min at room temperature, and then microwaved in citrate buffer (0.01 mol/L, pH 6.0) for 10 min for antigen retrieval. After blocking with 5\% bovine serum albumin, the sections were incubated with NKA primary antibody (dilution 1:400, Milipore, Germany) overnight at 4\(^\circ\)C. Subsequently, they were incubated with HRP-Anti-Mouse/Rabbit IgG secondary antibody (Abcam, China) for 30 min. After DAB (ZSGB, China) staining, sections were stained with hematoxylin. The data were then analyzed using Image-Pro Plus 5.10 software (Media Cybernetics, USA).

Cell culture

The human proximal tubular cells (HK-2 cells) were kindly provided by Renmin Hospital of Wuhan University. The cells were cultured at 37\(^\circ\)C in low glucose DMEM medium (HyClone, USA) containing 10\% heat-inactivated fetal bovine serum (FBS) (Gibco, USA), 100 U/mL penicillin G, 100 mg/mL streptomycin in the presence of 5\% \(\text{CO}_2\).

Ouabain treatment and subsequent assays

HK-2 cells were serum-starved for 12 h before treatment and then switched to low glucose DMEM medium with 10\% FBS. Subsequently different concentrations of ouabain (0 nM (control), 0.1 nM, 1 nM, 10 nM, 100 nM and 1000 nM) were added to treat HK-2 cells for 72 h. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was performed at 24 h, 48 h and 72 h to detect the cell viability; Annexin V-FITC (AV)/propidium iodide (PI) assay was conducted at 24 h to detect cell apoptosis.

The effect of ouabain on NKA, pSrc, pERK, pAkt, pS6K and caspase 3 expressions

To further investigate the effect of ouabain on cells apoptosis, 100 nM ouabain was added to treat HK-2 cells. NKA protein expression was detected by immunofluorescence (IF) assay and western blot (WB) at 0 h, 0.5 h, 1 h, 6 h, 12 h and 24 h after treatment. pSrc, pERK, pAkt, pS6K and caspase 3 protein expressions were
determined by WB assay at 0 h, 0.5 h, 1 h, 6 h, 12 h and 24 h after treatment.

**PP2 and rapamycin on regulating the effect of ouabain on pSrc, pERK, pAkt, pS6K and caspase 3 expressions**

Src kinase inhibitor (PP2) (Abcam, USA) and mTOR inhibitor (Rapamycin) (Sigma, USA) were then used to treat HK-2 cells with or without ouabain. Cells were divided into 6 groups according to the treatment: control, ouabain treatment group, PP2 treatment group, rapamycin treatment group, PP2+ ouabain treatment group, rapamycin + ouabain treatment group. pSrc, pERK, pAkt, pS6K, and caspase 3 protein expression were determined by WB at 24 h after treatment. For cells treated by ouabain and PP2 or rapamycin, the inhibitor was added 1 h before the addition of ouabain.

**MTT assay**

Cells viability was assessed by MTT reagent (Sigma, USA). First, 100 mg of MTT was dissolved in 20 mL phosphate-buffered saline (PBS) to make a 5 mg/mL solution. Next, 10 μl of MTT solution was added to each well, which contained 100 μl culture medium, and incubated at 37°C for 4 h. Then the culture medium in the wells was removed, and 100 μl of DMSO (Dimethyl sulfoxide) was added to each well, the solution was dissolved for 10 min. Finally, the plates were analyzed using a microplate reader (Molecular Devices, USA) at 490 nm.

**AV/PI assay**

Cells were digested by pancreatin and subsequently washed by PBS. After the cells were suspended in 100 μl Blinding Buffer, 5 μl AV (KeyGen Biotech, China) was added and placed in the dark for 15 mins at room temperature. 5 μl PI (KeyGen Biotech, China) was added just before flow cytometry assay. Flow cytometry was used to analyze the results.

**IF assay**

The cell films were fixed in 4% paraformaldehyde with 0.3% Triton X-100 (Goodbio, China) for 30 min at 4°C and stained with NKA antibody (dilution 1:100, DSHB, USA) overnight at 4°C. The films were then subjected to Alexa 488-conjugated IgG (Goodbio, China) at 37°C for 50 min. All microscopic images were recorded using Nikon eclipse Ci (Nikon, Japan).

**WB assay**

The cells were harvested and rinsed with ice-cold PBS and lysed in RIPA buffer (150 mM sodium chloride; 1.0% Triton X-100; 0.5% sodium deoxycholate; 0.1% sodium dodecyl sulfate; 50 mM Tris, pH 8.0) mixed with protease inhibitors (Merk-Millipore, USA) and phosphatase inhibitors (Roche, USA) for 30 min on ice. Samples were collected and centrifuged at 12,000 rpm for 15 min at 4°C. Supernatant protein was boiled in loading buffer at 100°C for 10 min. The protein samples were subjected to SDS-PAGE and transferred to PVDF membranes (Roche, USA). After blocking with 5% nonfat dried milk in TBS-T (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20, pH 8.0) for 1 h at room temperature, membranes were incubated with primary antibodies against NKAα1 (DSHB, USA), Phospho-Src/Src (Abcam, USA), Phospho-ERK/ERK (CST, USA), Phospho-Akt (Ser473)/Akt (Thr308) (CST, USA), Phospho-S6k (CST, USA)/S6K (Abcam, England), caspase 3 (CST, USA), GAPDH (Millipore, Germany) overnight at 4°C. HRP AffiniPure Goat Anti-Mouse/Rabbit IgG (Dilution 1:5000, Dako, USA) was used as secondary antibodies. The protein signals were detected using an ECL kit (GE, USA) and quantified using a Bio-Rad imaging densitometer (Bio-Rad, USA). The bands were analyzed with quantity one software Version 4.6.6 (Bio-Rad, USA).

**Statistics**

Each experiment was performed as triplicate. The statistical analysis was carried out by SPSS 22.0 (IBM, USA) and GraphPad Prism 6.0 (Graphpad, USA). Data were mainly presented as mean ± standard deviation or mean ± standard error. Comparison between two groups was determined by t test. P<0.05 was considered significant.

**Results**

**Serum ouabain expression in LN patients and HCs**

As shown in Figure 1, the level of ouabain in serum from LN patients was elevated com-
Ouabain in lupus nephritis

Figure 1. Serum ouabain concentration in lupus nephritis (LN) patients and healthy controls (HCs). Serum ouabain concentration was increased in LN patients (N=21) compared with HCs (N=20). Comparisons were determined by t-test. *P<0.05, **P<0.01, ***P<0.001. LN, lupus nephritis; HCs, healthy controls.

Figure 2. Kidney tissue NKA expression in LN patients and controls. NKA positive expression was not detected in the glomeruli, but in the renal tubule (A). NKA expression was decreased in LN patients (N=21) compared to controls (N=6) without LN who underwent nephrectomy (B). Comparisons were determined by t-test. *P<0.05, **P<0.01, ***P<0.001. LN, lupus nephritis; NKA, Na-K-ATPase α1.

Ouabain inhibited cells viability and promoted cells apoptosis in HK-2 cells

MTT assay revealed that cells viability was decreased at each time point (24 h, 48 h and 72 h) in ouabain 0.1 nM, 1 nM, 10 nM, 100 nM and 1000 nM groups compared with control group (0 nM). Comparisons were determined by t-test. *P<0.05, **P<0.01, ***P<0.001.

Ouabain inhibited cells viability and promoted cells apoptosis in HK-2 cells

NKA protein expression after ouabain treatment

IF assay showed that NKA protein expression was increased at 1 h and 6 h compared to 0 h, while dramatically decreased at 12 h and 24 h compared to 0 h after ouabain treatment (Figure 5A, 5B). WB also disclosed that NKA protein expression was initially increased at 0.5 h, 1 h and 6 h than 0 h, while subsequently decreased at 12 h and 24 h compared with 0 h after ouabain treatment (Figure 5C, 5D).

pSrc, pERK, pAkt, pS6K and caspase 3 expressions after ouabain treatment

WB (Figure 6A) showed that pSrc protein expression was increased at 1 h, 6 h and 12 h compared with 0 h (Figure 6B); pS6K protein...
Ouabain in lupus nephritis

Figure 4. Apoptosis of HK-2 cells after ouabain treatment. Cell apoptosis was detected by AV/PI assay (A) which showed that the apoptosis rate was increased at each time point (24 h, 48 h and 72 h) in ouabain 0.1 nM, 1 nM, 10 nM, 100 nM and 1000 nM groups compared with control group (0 nM) (B). Comparisons were determined by t-test. *P<0.05, **P<0.01, ***P<0.001.

Figure 5. NKA expression in HK-2 cells after ouabain treatment. NKA expression was detected by immunofluorescence assay and western blot at 0 h, 0.5 h, 1 h, 6 h, 12 h and 24 h after 100 nM ouabain treatment. NKA expression was elevated at 1 h and 6 h while reduced greatly at 12 h and 24 h compared to 0 h after ouabain treatment by immunofluorescence assay (A, B). Western blot assay also revealed that NKA expression was increased at 0.5 h, 1 h and 6 h while critically decreased at 12 h and 24 h compared with 0 h after ouabain treatment (C, D). Comparisons were determined by t-test. *P<0.05, **P<0.01, ***P<0.001. NKA, Na-K-ATPase α1.

was elevated at 1 h and 6 h compared to 0 h (Figure 6E); and pERK protein (Figure 6C), pAkt protein (Figure 6D) and caspase 3 protein (Figure 6F) were all increased at 0.5 h, 1 h, 6 h,
Figure 6. pSrc, pERK, pAkt, pS6K, and caspase 3 expression in HK-2 cells after ouabain treatment. pSrc, pERK, pAkt, pS6K and caspase 3 expressions were determined by western blot, which showed that they were all activated after ouabain treatment (A-F). Comparisons were determined by t-test. *P<0.05, **P<0.01, ***P<0.001.
Ouabain in lupus nephritis

12 h and 24 h compared to 0 h. These indicated ouabain might regulate HK-2 cells viability and apoptosis through modulating NKA, pSrc, pERK, pAkt, pS6K and caspase 3 expressions.

**Discussion**

In this present study, we observed that: (1) Circulating ouabain was elevated in LN patients compared with HCs, and NKA expression in kidney tissue of LN patients was decreased versus controls. (2) Ouabain promoted HK-2 cell apoptosis while inhibiting proliferation in a dose-dependent way. (3) Ouabain decreased NKA expression and activated pSrc, pERK, pAkt, pS6K, and caspase 3 expressions.

SLE is a multisystem autoimmune disorder disease which presents with a broad spectrum of effects on multiple organs including the kidney, and it is estimated that 28-70% of patients with SLE will develop LN [4, 11]. A recent comprehensive review discloses that the prevalence of LN in United States ranges from 50-70 per 100,000 persons in different socioeconomic groups [3], which not only increases patients’ functional burden but also economic burden [12]. Thus, investigation of the underlying mechanism of LN pathogenesis is of great importance.

Ouabain belongs to a group of compounds (the cardiotonic steroids), which are composed of a steroidal backbone, the aglycone, or genin; a five-membered unsaturated lactone ring; and a sugar moiety, which varies depending on the type of cardenolide [13]. It is reported to have a critical role in several kidney diseases [13-15]. In a previous animal experiment, ouabain has been observed to induce kidney damage in renal ischemia-reperfusion injury rat model [9]; and ouabain preoperative plasma level could be used as a convincing biomarker for AKI risk in patients undergoing cardiac surgery; in addition, ouabain is observed to be upregulated in chronic kidney disease patients [10, 11, 16]. These findings indicate ouabain contributes to the development and/or progression of kidney disease. In this present study, we found serum ouabain was increased in LN patients compared with HCs, which might result from ouabain causing kidney injuries by multiple mechanisms; thus it was upregulated in LN patients.

Some studies show that ouabain induces cell apoptosis and suppresses cell proliferation by regulating multiple pathways such as in Burkitt’s lymphoma Raji cells, glioblastoma cells, cochlear hair cells and lung cancer cells [7, 8, 17, 18]. Other studies reveal that ouabain inhibits cell apoptosis and improves cell proliferation, as in autosomal dominant polycystic kidney disease cells, leukemia cells and vascular smooth muscle cells [19, 20]. This implies that ouabain may present with dual effects on cell proliferation and apoptosis. Further studies in several cell lines support this inference. A recent experiment illustrates that ouabain presents with dual effects on regulating human umbilical vein endothelial cells proliferation and apoptosis involving NKA and NF-κB pathways [21]. Another experiment shows a dual effect of ouabain on cell apoptosis in human fibroblasts [22]. These studies disclose that a low dose of ouabain promotes cells proliferation and inhibits cell apoptosis, while middle or high dose of ouabain suppresses cell proliferation and induces cell apoptosis, which depends on the expression of NKA after ouabain intervention [21, 22]. However, there is little data on the role of ouabain and NKA in LN. In this study,
we found kidney tissue NKA expression was decreased in LN patients compared with controls, which indicated NKA downregulation might be involved in the etiology of LN. We found ouabain promoted HK-2 cells apoptosis while it inhibits proliferation in a dose-dependent way; moreover, ouabain decreased NKA expression and activated pSrc, pERK, pAkt, pS6K and caspase 3 expression. These findings implied ouabain may contribute to LN development and progression by modulating NKA, pSrc, pERK, pAkt, pS6K and caspase 3.

In conclusion, ouabain may contribute to the etiology of LN by inhibiting human proximal tubular cell viability and promoting cell apoptosis by regulating NKA, pSrc, pERK, pAkt, pS6K and caspase 3.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (No. 81400734) and the Natural Science Foundation of Hubei Province of China (No. 2015CBF241).

Disclosure of conflict of interest

None.

Address correspondence to: Wenli Chen, Division of Nephrology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 26 Shengli Street, Wuhan 430014, China. Tel: +86-27-82211488; Fax: +86-27-8281-1446; E-mail: chenwenlyy@163.com

References


Ouabain in lupus nephritis


